Skip to main content
  • Where to buy
  • Company
    • About us
    • Careers
    • Events
  • Support
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Contact
  • U.S.A.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
Home ELGA LabWater
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA Full Product Range
  • Applications
    • Atomic Absorption Spectroscopy
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • Immunochemistry
    • Liquid Chromatography
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • Blog
    • Case Studies
    • Ultrapure water
    • Guides and White Papers
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • ELGA Full Product Range
      • PURELAB® Classic
  • Applications
    • Atomic Absorption Spectroscopy
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • Immunochemistry
    • Liquid Chromatography
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Case Studies
      • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA: The biggest medical diagnostics company in Brazil
      • ELGA helps immuneserology labs maximize uptime
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • Importance of ultrapure Type 1+ water for the development of generic medicines
      • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex: an ideal training system for today's research method
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Unlocking the secrets of the Antarctic with the aid of ultrapure water
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Ultrapure water
    • Guides and White Papers
      • HPLC Water Purity
      • HPLC in Pharma
      • Reducing Clinical Risks
      • Sustainability
  • U.S.A.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum

Let's talk about lab water

  • Categories
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment & Sustainability
    • Future Science
    • Life in The Lab
    • PURELAB Product Design
    • Science of the Future
    • Water In The Lab
    • Water Purity
  • Authors
    • ELGA Editorial Team_cloned
    • ELGA Editorial Team
    • Natasha Zarach
    • Dr Paul Whitehead
    • Dr Alison Halliday
    • John Walker
Clinical & Pharma
Science of the Future

What’s the Future of Pharma?

25 Jan 2020
- by ELGA Editorial Team

Medicine doctor and stethoscope touching icon heart and diagnostics analysis medical on modern virtual screen interface network connection. Medical technology diagnostics of heart concept

The pharmaceutical industry has been in a very specific transition in the last decade: new business models, regulatory changes (e.g. cold WFI), challenges in the German healthcare system (e.g. an aging population) and a growing demand for pharmaceutical products in emerging markets determined the direction . Where is the industry headed now and how will the pharmaceutical industry use laboratory water – probably its most important resource – effectively in the future?


A changing landscape

A decline in the traditional small molecule drug development pipeline and fierce generic competition mean the era of “blockbuster” drugs may be over. To remain financially sustainable, many companies have shifted their focus to new, large-molecule biologic drugs. In 2008, biopharmaceuticals accounted for just 16% of pharmaceutical sales. In 2019 it was already 27.4%.

Novel biological therapeutics bring with them a number of additional manufacturing challenges. They are more prone to contamination in the production process than traditional small molecule drugs, and manufacturers need to ensure that production conditions are carefully controlled. For example, the production of biologics based on monoclonal antibodies requires a significant amount of  ultrapure water for cell culture  and downstream processing.

Other up-and-coming areas such as nanomedicine and stem cell treatments also pose special challenges in terms of ensuring production quality. Regenerative medicines, for example, are based on tissue samples from the patient and therefore many of the preparation steps have to be carried out in closed systems at the "point of care". The establishment of compact, sterile production facilities will be essential to ensure the highest level of patient safety and treatment efficiency.

Regulatory processes influence market launch

Regulatory approval processes will also evolve as new methods of evaluating, approving and monitoring the safety and efficacy of these medicines emerge. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are now placing a much greater focus on post-market surveillance to ensure patient safety. EMA, for example, recently ran a pilot program for ' adaptive approval ', in which new therapies are approved on the basis of further testing to confirm their safety and effectiveness in different patient populations.

For the pharmaceutical industry, this means that traditional approaches to launching products are likely to give way to a phased approach, where demand for a product increases as a license is renewed. However, as the time lag between a product's launch and peak sales increases, so does the time it takes to recoup spending on manufacturing infrastructure. Therefore, rather than investing conventionally in a manufacturing facility designed to meet maximum demand from day one, a company bringing a new drug to market will increasingly need a flexible supply chain that can quickly adjust as approval changes changes.

In order to be able to cope with these shifts in demand, manufacturers must also provide an infrastructure that can be easily expanded. For example, traditional scale-up approaches could be replaced by "numbering-up," where additional micromodules are simply added as needed. Modular systems for the production of laboratory water  for pharmaceutical companies that can use this "Lego-like" structure of micro-reaction technology then offer advantages over fixed systems.

Growing environmental pressure also for pharmaceutical companies

Of course, the pharmaceutical sector is not immune to global developments in the sustainability and eco-friendliness issues facing the industry in general, particularly when it comes to water consumption. The UN predicts that by 2025, 1.8 billion people will be living in regions of severe water stress, while 5 billion will be living in "water stress" conditions. This problem will acutely affect parts of China, India and sub-Saharan Africa. Germany will have to face this phenomenon more and more frequently in phases.

As the pharmaceutical industry is a large consumer of water, this issue will increasingly influence decisions about the siting of production facilities and the use of resource-efficient systems. This will mainly, but not only, affect regions in emerging markets. For sustainable growth, the pharmaceutical industry must ensure that it uses the best possible solutions throughout the drug development process to minimize its water footprint. Energy-efficient systems that use resources intelligently, e.g. Devices such as those that can control the flow rate depending on the application will play an important role in overcoming these challenges.

Conclusion

As the pharmaceutical industry evolves to meet tomorrow's healthcare needs, it is clear that water purification and laboratory water production will play a crucial role. Increasingly efficient and flexible purification systems will be essential to provide the ultrapure water needed for the sustainable production of innovative therapies. By working with technology providers like Veolia's ELGA Labwater, the industry can continue to provide safe and effective treatments to those who need them.

 

Quest Download

PURELAB Quest

The only purifier on the market that dispenses all 3 types of science ready water from a compact, economical and easy to use system!

             Click Here To Find Out More

 

Highlights

4 Aug 2022
Pesticides in Dutch drinking water
1 Aug 2022
Das bringt die Zukunft für die Pharmaindustrie und ihr Laborwasser
25 Jul 2022
Exploring natural compounds for mastitis control
18 Jul 2022
A new photothermal device for seawater desalination
11 Jul 2022
Paving the way for clean 3D bioprinting
4 Jul 2022
Monitoring the quality of drinking water in South Korea
27 Jun 2022
Is it time to ditch reusable plastic water bottles?
20 Jun 2022
Honeysuckle berries: a promising source of bioactive compounds

Categories

  • Analytical Chemistry
  • Clinical & Pharma
  • Cool Science
  • Environment & Sustainability
  • Future Science
  • Life in The Lab
  • PURELAB Product Design
  • Science of the Future
  • Water In The Lab
  • Water Purity

Video

  • Enquiry
  • Get a Quote
  • Book a Demo
  • Find an Approved Partner

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Get a Quote

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Book a Demo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

ELGA LabWater North America
5 Earl Ct Suite 100
Woodridge, IL 60517
USA

Tel: 630-343-5251

ELGA LabWater UK Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Case Studies

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Resources

  • Learn About Ultrapure Water
  • Guides and White Papers
  • Purification Technologies
  • Applications
  • Impurities In Water

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd. trading as ELGA LabWater. 2022 - All rights reserved.
ELGA is the global laboratory water brand name of Veolia.

  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia